Novalgen Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The global Small Lymphocytic Lymphoma Treatment market has significantly grown over the past few years and is expected to register rapid growth. Revenue...

NovalGen announces one oral and one poster presentation at the 65th American Society of Hematology Annual Meeting...

- First clinical data for NVG-111, a novel ROR1xCD3 bispecific antibody in patients with relapsed / refractory CLL and MCL - Early data demonstrates...

NovalGen doses first patient in Phase I study in Chronic Lymphocytic Leukemia & Mantle Cell Lymphoma  –  NVG-111 is the first-in-class T-cell engager that simultaneously binds CD3 on T-cell and ROR1 on tumor cells – London, United Kingdom, June 9, 2021 – NovalGen Ltd (“Nova...

    LONDON, United Kingdom and LEIDEN, The Netherlands, February 22, 2021 / B3C newswire / --NovalGen Ltd. (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies and HALIX B.V. (“HALIX”), a contract development and manufacturing organisation, today announced a strategic partnership. Within the scope of this partnership, HALIX will provide manufacturing of clinical supply of NovalGen’s therapies. NovalGen’s innovative platform technology has been successfully deployed at HALIX to manufacture clinical trial material for NovalGen’s first clinical progr...